Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2017JAMA OncologyOpen Access

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWilliam L. HwangBroad InstituteANAndrzej NiemierkoHarvard UniversityKHKatie L. HwangHarvard University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hwang et al. (2017) studied this question.

synapsesocial.com/papers/6a8d3ffef59d2089034ac413https://doi.org/10.1001/jamaoncol.2017.3808
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma2012 · 2,103 citations
  2. 2Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma2017 · 1,168 citations
  3. 3Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016 · 10,336 citations
  4. 4Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015 · 9,577 citations
  5. 5Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,648 citations